1. In Vivo
  2. >>Deal-Making

In Vivo's Deals Of The Month, February 2017

 
• By Nancy Dvorin

Free article: In Vivo's editors pick February's most significant deals, including Seattle Genetics' new ADC and Integra's big bid in neurosurgery.

IV_DOTM_1200

Seattle Genetics Inc., the first company to gain FDA approval for an antibody-drug conjugate, has licensed rights to a breast cancer ADC that has been designated a potential breakthrough therapy. Seattle will pay $250 million up front to Immunomedics Inc. for global rights to sacituzumab govitecan (IMMU-132). Immunomedics can earn development, regulatory and sales-based milestone payments up to $1.7 billion, along with tiered double-digit royalties. Seattle also purchased a 2.8% equity stake in Immunomedics and can buy 8.7 million additional shares in the company through an unspecified date. [See Deal]

Sarepta Therapeutics Inc. has sold the voucher it received upon approval of its Duchenne muscular dystrophy treatment Exondys 51...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By Ashley Yeo

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

Deals In Depth: April 2025

 
• By Deanna Kamienski and Maureen Riordan

Four $1bn+ alliances were penned in April, and one exceeded $2bn.

Deals Shaping The Industry, April 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during April 2025. Data courtesy of Biomedtracker.

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By David Wild

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By Ashley Yeo

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By Ashley Yeo

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.